secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001213900-23-039171
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Blue Water Biotech Q1 net loss $2.8M, cash $20.3M, ENTADFI acquisition closed
-----------------------------------------------------------------------------

- Net loss of $2.8M in Q1 2023 vs $2.1M in Q1 2022; cash $20.3M, down from $25.8M at Dec 2022.
- Acquired ENTADFI (FDA-approved BPH treatment) for up to $100M; $20M upfront payable in tranches through Sep 2024.
- Appointed Frank Jaeger as SVP Marketing & Business Development for ENTADFI launch; Timothy Ramdeen joined board.
- Partnered with AbVacc to develop vaccine candidates targeting monkeypox and Marburg using norovirus VLP platform.
- Signed research agreement with UT Health San Antonio for non-human primate study of Chlamydia vaccine BWV-401.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023039171/0001213900-23-039171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023039171/ea178509-8k_bluewater.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-039171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer